Testing effectiveness (Phase 2)WithdrawnNCT00446173What this trial is testingAutologous Stem Cell Transplants for Chronic Myelogenous LeukemiaWho this might be right forLeukemia M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT00816283What this trial is testingDasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaWho this might be right forLeukemia City of Hope Medical Center 5
Early research (Phase 1)Study completedNCT00316953What this trial is testingDasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChildhood Chronic Myelogenous Leukemia+5 more National Cancer Institute (NCI) 48
Post-approval studies (Phase 4)Study completedNCT00171899What this trial is testingStudy Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)Who this might be right forChronic Myelogenous Leukemia Novartis Pharmaceuticals 80
Testing effectiveness (Phase 2)Study completedNCT00809211What this trial is testingNilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaWho this might be right forLeukemia Cancer Trials Ireland 40
Early research (Phase 1)Study completedNCT01159028What this trial is testingClinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDSWho this might be right forRecurrent Adult Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome+1 more Bio-Path Holdings, Inc. 60
Testing effectiveness (Phase 2)Ended earlyNCT00003561What this trial is testingInterferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaWho this might be right forLeukemia Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 48
Testing effectiveness (Phase 2)Study completedNCT00103844What this trial is testingDasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid LeukemiaWho this might be right forChronic Myeloid LeukemiaPhiladelphia-Positive Myeloid Leukemia Bristol-Myers Squibb 150
Testing effectiveness (Phase 2)Ended earlyNCT00015847What this trial is testingImatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous LeukemiaWho this might be right forLeukemia OHSU Knight Cancer Institute 25
Not applicableStudy completedNCT00068523What this trial is testingUltraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic MalignanciesWho this might be right forChronic Myeloproliferative DisordersLeukemiaLymphoma+3 more Case Comprehensive Cancer Center 10
Testing effectiveness (Phase 2)Study completedNCT00384228What this trial is testingA Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALLWho this might be right forChronic Myelogenous LeukemiaAcute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) Novartis Pharmaceuticals 42
Large-scale testing (Phase 3)Study completedNCT02272777What this trial is testingImatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseWho this might be right forLeukemia Novartis Pharmaceuticals 225
Not applicableNo Longer AvailableNCT01549548What this trial is testingCompassionate Use PonatinibWho this might be right forPhiladelphia Chromosome Positive (Ph+) LeukemiasChronic Myeloid Leukemia OHSU Knight Cancer Institute
Large-scale testing (Phase 3)Ended earlyNCT00004933What this trial is testingHomoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon AlfaWho this might be right forLeukemia Alliance for Clinical Trials in Oncology 5
Testing effectiveness (Phase 2)Study completedNCT00390793What this trial is testingCombination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.Who this might be right forAcute Lymphoblastic LeukemiaBCR-ABL1 Fusion Protein ExpressionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+3 more M.D. Anderson Cancer Center 107
Testing effectiveness (Phase 2)Study completedNCT00244829What this trial is testingImatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive LeukemiaWho this might be right forLeukemia Fred Hutchinson Cancer Center
Early research (Phase 1)Study completedNCT01460498What this trial is testingAzacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)Who this might be right forLeukemia M.D. Anderson Cancer Center 3
Early research (Phase 1)Study completedNCT00301093What this trial is testingVaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaWho this might be right forLeukemia Dana-Farber Cancer Institute 3
Large-scale testing (Phase 3)Ended earlyNCT00519090What this trial is testingNilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)Who this might be right forMyelogenous Leukemia Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)Ended earlyNCT01357655What this trial is testingPhase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)Who this might be right forLeukemia Bristol-Myers Squibb 70